Episurf Medical AB (publ) ("Episurf", "Episurf Medical" or the "Company"), (NASDAQ Stockholm: EPIS B) has during the second quarter of 2024 carried out an issue of units consisting of shares of series B and warrants of series TO13 B ("Units") with preferential rights for existing shareholders and a subsequent set-off issue of Units to guarantors in the rights issue. The period for exercising warrants of series TO13 B to subscribe for shares ran from and including 10 February 2025 up to and including 24 February 2025. In total, 1,586,850 warrants of series TO13 B were exercised for subscription of the same number of new shares of series B, corresponding to an exercise rate of approximately 1.03 percent.

One (1) warrant of series TO13 B entitled the holder to subscription of one (1) new share of series B in the Company at a subscription price of SEK 0.24 per share. Through the exercised warrants, Episurf will thus receive 380,844 SEK before costs attributable to the rights issue.

Through the exercise of warrants of series TO13 B, the number of shares in Episurf increases by 1,586,850 shares of series B, from a total of 651,477,842 shares to 653,064,692 shares, of which 473,357 are shares of series A and 652,591,335 are shares of series B. The share capital increases by SEK 15,868.50 to SEK 6,530,646.92. The total number of votes in the Company after the exercise of warrants of series TO13 B amounts to 654,011,406. The exercise of warrants of series TO13 B entails a dilution effect of approximately 0.24 percent in relation to the number of shares and approximately 0.24 percent in relation to the number of votes in the Company.

Exercised warrants of series TO13 B have been replaced with interim shares (IA) pending registration of the new shares of series B with the Swedish Companies Registration Office. The conversion of interim shares to shares of series B is expected to take place approximately one week after registration with the Swedish Companies Registration Office.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 17.15 CET on 25 Februay 2025.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Episurf Medical in any jurisdiction, neither from Episurf Medical nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus, prepared in accordance with the simplified disclosure regime for secondary issuances as set forth in the Prospectus Regulation, regarding the rights Issue described in this press release has been prepared by the Company, reviewed and approved by the Swedish Financial Supervisory Authority and published on the Company's website.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the US, the United Kingdom, Australia, Belarus, Canada, Hong Kong, Israel, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.